Highlights
- •We assessed the clinical importance of CSF Aβ42 in MCI, AD and non-AD dementias.
- •We found that Aβ42 was significantly lower in AD compared to MCI, FTD, PDD and VaD.
- •Despite the debate, Aβ42 was indeed moderately lower in AD compared to DLB.
- •Aβ42 was significantly lower in AD than in PD (with or without dementia).
- •This meta-analysis implies that CSF Aβ42 is a good biomarker for discriminating AD.
Abstract
Mild Alzheimer's disease (AD) is usually difficult to differentiate from other dementias
or mild cognitive impairment (MCI). The aim of our study is to evaluate the clinical
importance of cerebrospinal fluid (CSF) β-amyloid 42 (Aβ42) in MCI, AD and other dementias, more specifically: frontotemporal dementia (FTD),
dementia with Lewy bodies (DLB), Parkinson's disease (PD) with dementia (PDD) and
vascular dementia (VaD). Fifty eligible articles were identified by search of databases
including PubMed, EMBASE, Elsevier, Springer Link and the Cochrane Library, from January
1990 to May 2014. The random effects model was used to calculate the standardized
mean difference (SMD) with corresponding 95% CI by STATA 9.0 software. The subgroup
analyses were made on the method (ELISA, xMAP). We found that CSF Aβ42 concentrations were significantly lower in AD compared to MCI (SMD: −0.68, 95% CI: [−0.80, −0.56], z = 11.34, P < 0.001), FTD (SMD: −1.09, 95% CI: [−1.41, −0.76], z = 6.62, P < 0.001), PDD (SMD: −0.75, 95% CI: [−1.39, −0.10], z = 2.27, P = 0.023), VaD (SMD: −0.95, 95% CI: [−1.30, −0.61], z = 5.43, P < 0.001). In addition, compared to DLB, Aβ42 concentrations are moderately lower in AD (SMD: −0.27, 95% CI: [−0.51, −0.03], z = 2.20, P = 0.028). Results from this meta-analysis hinted that CSF Aβ42 is a good biomarker for discriminating Alzheimer's disease from other dementias and
MCI.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Tau and p-tau as CSF biomarkers in dementia: a meta-analysis.Clin Chem Lab Med. 2011; 49: 353-366
- Epidemiology and risk factors of dementia.J Neurol Neurosurg Psychiatry. 2005; 76: v2-v7
- Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease.Neurology. 1984; 34: 939-944
- Preclinical AD Workgroup staging: pathological correlates and potential challenges.Neurobiol Aging. 2012; 33: 622.e1-622.e16
- Biological markers for therapeutic trials in Alzheimer's disease.Neurobiol Aging. 2003; 24: 521-536
- Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline.Eur J Neurol. 2007; 14: e1-e26
- Pathways towards and away from Alzheimer's disease.Nature. 2004; 430: 631-639
- Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease.Front Biosci. 2012; 17: 2024-2034
- Fluid biomarkers in Alzheimer disease.Cold Spring Harb Perspect Med. 2012; 2: a006221
- The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.Science. 2002; 297: 353-356
- Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.Clin Chem Lab Med. 2011; 49: 367-374
- Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers.Clin Chem. 2013; 59: 903-916
- The development of effective biomarkers for Alzheimer's disease: a review.Int J Geriatr Psychiatry. 2013; 28: 331-340
- A power primer.Psychol Bull. 1992; 112: 155-159
- Computing effect size measures with ViSta—the visual statistics system.Tutor Quant Methods Psychol. 2009; 5: 25-34
- Evaluation of CSF-tau and CSF-A-beta-42 as diagnostic markers for Alzheimer disease in clinical practice.Arch Neurol. 2001; 58: 373-379
- Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.Exp Neurol. 2001; 172: 433-436
- Core biological marker candidates of Alzheimer's disease—perspectives for diagnosis, prediction of outcome and reflection of biological activity.J Neural Transm. 2004; 111: 247-272
- Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.Lancet Neurol. 2006; 5: 228-234
- Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.Mech Ageing Dev. 2006; 127: 129-132
- Longitudinal changes of CSF biomarkers in memory clinic patients.Neurology. 2007; 69: 1006-1011
- Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.Dement Geriatr Cogn Disord. 2009; 27: 458-464
- Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease.Neurology. 2009; 73: 935-940
- Relationships between biomarkers in aging and dementia.Neurology. 2009; 73: 1193-1199
- Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment: 4-year follow-up in a routine clinical setting.Sci World J. 2009; 9: 961-966
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.Ann Neurol. 2009; 65: 403-413
- Glycemia and levels of cerebrospinal fluid amyloid and tau in patients attending a memory clinic.J Am Geriatr Soc. 2010; 58: 1318-1321
- Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer's disease.Eur J Nucl Med Mol Imaging. 2010; 37: 589-593
- Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline.Neurobiol Aging. 2010; 31: 1419-1428
- Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.Arch Neurol. 2010; 67: 688-696
- Tau-proteins as gender-specific state markers in amnestic mild cognitive impairment.Dement Geriatr Cogn Disord. 2010; 30: 93-100
- Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment.Neurobiol Aging. 2010; 31: 1452-1462
- Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.Neurobiol Aging. 2010; 31: 758-764
- Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.J Alzheimers Dis. 2010; 21: 471-478
- Relations between brain tissue loss, CSF biomarkers and the ApoE genetic profile: a longitudinal MRI study.Neurobiol Aging. 2010; 31: 1340-1354
- Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers.Dement Geriatr Cogn Disord. 2011; 32: 164-170
- CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease.Neurology. 2011; 77: 35-38
- Alzheimer's disease neuroimaging initiative. Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts.J Am Geriatr Soc. 2011; 59: 1705-1710
- Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum.Psychiatry Res. 2011; 192: 140-146
- SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer's disease.Eur Arch Psychiatry Clin Neurosci. 2012; 262: 529-534
- Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease.Biol Psychiatry. 2012; 71: 829-835
- CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease.PLoS One. 2012; 7: e30525
- CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging.J Neural Transm. 2000; 107: 563-579
- Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta amyloid induced by disparate mechanisms.Dement Geriatr Cogn Disord. 2002; 13: 112-118
- Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias.Dement Geriatr Cogn Disord. 2006; 21: 9-15
- Neuropsychological and behavioural correlates of CSF biomarkers in dementia.Neurochem Int. 2006; 48: 286-295
- Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.Neurobiol Aging. 2006; 27: 1202-1211
- Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration.J Neurol. 2008; 255: 539-544
- The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.Curr Alzheimer Res. 2010; 7: 470-476
- Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects.J Alzheimers Dis. 2010; 20: 445-452
- Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia.J Alzheimers Dis. 2011; 26: 553-563
- Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.Alzheimers Dement. 2013; https://doi.org/10.1016/j.jalz.2013.05.1775
- Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies.Neurology. 2000; 54: 1875-1876
- Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.Clin Chem Lab Med. 2006; 44: 192-195
- Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study.J Neurol Sci. 2007; 260: 33-37
- Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.Biol Psychiatry. 2008; 64: 850-855
- CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.Brain Res. 2009; 1251: 1-6
- Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.J Neurol Neurosurg Psychiatry. 2010; 81: 608-610
- CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.J Neurol Neurosurg Psychiatry. 2011; 82: 160-164
- Altered CSF orexin and α-synuclein levels in dementia patients.J Alzheimers Dis. 2012; 29: 125-132
- Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.J Neurosci Res. 2001; 66: 510-516
- Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia.Neurosci Lett. 2005; 383: 12-16
- Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia.J Gerontol A Biol Sci Med Sci. 2006; 61: 755-758
- Low specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate Alzheimer's disease from vascular dementia.J Gerontol A Biol Sci Med Sci. 2007; 62: 923-924
- Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review.Dement Geriatr Cogn Disord. 2008; 25: 256-265
- Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease.Ann Neurol. 1999; 45: 358-368
- CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.Neurology. 2003; 60: 652-656
- Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.Ann Neurol. 2006; 59: 512-519
- PET imaging of amyloid deposition in patients with mild cognitive impairment.Neurobiol Aging. 2008; 29: 1456-1465
- Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.Biol Psychiatry. 2009; 65: 927-934
- Low frequency of postlumbar puncture headache in demented patients.Acta Neurol Scand. 1993; 88: 221-223
- Fluid biomarkers in Alzheimer's disease-current concepts.Mol Neurodegener. 2013; 8: 20-30
- International quality control survey of neurochemical dementia diagnostics.Neurosci Lett. 2006; 409: 1-4
Article info
Publication history
Published online: July 14, 2014
Accepted:
July 7,
2014
Received in revised form:
May 27,
2014
Received:
April 17,
2014
Identification
Copyright
© 2014 Elsevier B.V. Published by Elsevier Inc. All rights reserved.
